TIANXIN PHARMA(SH:603235) Shang Hai Zheng Quan Bao·2026-01-05 19:49Core Viewpoint - Jiangxi Tianxin Pharmaceutical Co., Ltd. is set to list 290,714,800 restricted shares for trading on January 12, 2026, following the expiration of the lock-up period for these shares [2][4][6]. Group 1: Stock Listing Details - The total number of shares to be listed is 290,714,800 [3][14]. - The shares being listed are part of the company's initial public offering (IPO) and were approved by the China Securities Regulatory Commission on June 13, 2022 [5]. - The IPO involved issuing 43.78 million shares at a price of 36.88 yuan per share, resulting in a total share capital of 437,780,000 shares, with 394,000,000 shares subject to trading restrictions [5]. Group 2: Shareholder Information - The restricted shares are held by five shareholders, including Xu Jiangnan and Xu Jing, who collectively own 262,714,800 shares, which will have their lock-up period extended by 6 months due to commitments made during the IPO [6]. - The total restricted shares represent 66.41% of the company's total share capital [6]. Group 3: Lock-up Commitments - Shareholders have made commitments regarding the lock-up period, including not transferring shares during the initial 36 months and adhering to specific conditions for any future share sales [8][10][11]. - If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period will automatically extend for at least 6 months [9]. Group 4: Compliance and Verification - The underwriter, CITIC Securities Co., Ltd., has confirmed that the shareholders have complied with their commitments regarding the restricted shares [13]. - There are no reported instances of fund occupation by controlling shareholders or related parties [12].